Loan & DebtMay 11, 2026, 04:08 PM
Viridian Therapeutics Completes $250M Convertible Notes Offering
AI Summary
Viridian Therapeutics, Inc. completed its public offering of $250 million aggregate principal amount of 1.75% Convertible Senior Notes due 2032, including the full exercise of the underwriters' over-allotment option. The notes, issued on May 11, 2026, are unsecured senior obligations accruing interest semiannually. They are convertible under specific conditions at an initial rate of 40.5680 shares per $1,000 principal, representing an initial conversion price of approximately $24.65 per share, and are redeemable by the company from May 20, 2030, under certain stock price conditions.
Key Highlights
- Completed public offering of 1.75% Convertible Senior Notes due 2032.
- Raised $250,000,000 aggregate principal amount, including over-allotment.
- Notes accrue interest at 1.75% per year, payable semiannually.
- Initial conversion rate is 40.5680 shares per $1,000 principal amount.
- Initial conversion price is approximately $24.65 per share.
- Notes mature on May 15, 2032, unless earlier converted or redeemed.
- Company can redeem notes from May 20, 2030, under specific conditions.